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Objectives: Osteoarthritis (OA) is known to be a slowly progressive disease that alters all tissue 
compartments of the joint involved with a characteristic degradation of the cartilage, bone 
remodeling, and inflammation. One of the prominent symptoms in OA patients is pain, but a few 
radiological, inflammatory or structurally related biomarkers have shown little if any associations to 
pain. This study aimed to assess serum levels of 92 markers involved in inflammatory pathways in 
patients with knee OA (KOA) and evaluate their possible associations with the clinical pain 
intensity. 
Methods: Serum samples were collected from 127 knee KOA patients and 39 healthy participants 
with no knee pain. Each serum sample was analyzed for 92 inflammatory markers using the 
Proximity Extension Array (PEA) technology. Clinical pain intensity was assessed using a visual 
analog scale, and patients completed the Knee Injury and Osteoarthritis Outcome Score (KOOS) 
questionnaire. 
Results: Fifteen markers were significantly different when comparing KOA patient and healthy 
participants. Two markers, fibroblast growth factor-21 (FGF-21) and Eukaryotic translation 
initiation factor 4E-binding protein 1 (4E-BP1), correlated positively with pain intensity (R=0.235, 
P=0.008; R=0.233, P=0.008). Moreover, a linear regression model showed interleukin-6 (IL-6), 
macrophage colony-stimulating factor 1 (CSF-1), FGF-21 and tumor necrosis factor superfamily 
member 12 (TWEAK) as significant independent parameters for pain intensity. 
Discussion: The associations between specific cytokines and KOA pain intensities provide new 
insights into the understanding of the underlying factors driving the pain in OA. 
Keywords: knee osteoarthritis, inflammation biomarker, pain, proteomics. 
  






Osteoarthritis (OA) is a painful disease mostly affecting the elderly population, one of the leading 
causes of disability 
1
, and becoming more prevalent 
2
. One of the prominent symptoms in OA 
patients is pain, and due to the lack of effective and safe therapies this represents a specific unmet 
medical need 
3,4
. OA is known to be a slowly progressive disease that alters all tissue compartments 
of the joint involved with a characteristic degradation of the cartilage, bone remodeling, and 
inflammation response 
5
. Previously OA has not been defined as a predominantly inflammatory 
disease 
6
 but more recent findings indicate that chronic inflammatory processes may be a driver in 
OA progression and pain 
7
. 
A study has shown that the progression of cartilage disruption and the presence of a reactive 
inflammatory synovium present a link 
8
. Kapoor et al. reviewed the action of secreted inflammatory 
factors, such as proinflammatory cytokines as a critical mediator of the altered metabolism, and 
augmented catabolism of the joint tissue in the pathogenesis of OA 
9
. 
It has also been suggested that cytokines may act as biochemical markers of OA severity and pain 
intensity 
10
. Cytokines which are a broad category of small proteins (~5–20 kDa) involved in cell 
signaling are also proteins that can act as key mediators in inflammatory processes, with numerous 
cytokines and related signaling pathways involved in the onset and pathogenesis of OA 
11,12
. 
Preclinical data shows that proinflammatory cytokines sensitize the peripheral nerve endings, which 
may eventually contribute to changes in central pain processing 
13,14
, a manifestation seen in OA 
patients 
15,16
. This indicates that the assessment of inflammatory mediators in circulation could be 
prognostic, and that pain biomarkers are a way to explore new therapeutic opportunities and pave 
the way for individualized management. A recent study found that a subgroup of OA patients are 
characterized by systemic low grade inflammation 
17
. More specifically, Interleukin-6 has been 





suggested to be up-regulated in patients with high synovitis scores 
18




To further investigate the influence of inflammatory markers in OA pain, the current study aimed 
to, 1) evaluate the serum level of inflammatory markers, using a new high throughput proteomic 
approach to look at the serum levels of 92 polypeptides involved in inflammatory processes in 
serum of patients with knee OA compared with healthy participants and, 2) evaluate the association 
between the pain intensity, the Knee Injury and Osteoarthritis Outcome Score (KOOS), and serum 
biomarker levels. 
2. MATERIAL AND METHODS 
2.1 Patients 
One hundred and twenty-seven patients with KOA scheduled for total knee replacement (TKR) 
were recruited from the outpatient clinic at Hospital Vendsyssel, Frederikshavn, Denmark. Patients 
with other diagnosed pain conditions (e.g., hip OA, rheumatoid arthritis, fibromyalgia, and 
neuropathic pain) or mental impairment were excluded from the study. Radiological KOA was 
evaluated using the Kellgren and Lawrence (KL) score 
20
. The patients were asked not to take any 
analgesic medication 24 hours before the study visit. The study was approved by The North 
Denmark Region Committee on Health Research Ethics (N-20120015) and conducted in 
accordance with the Helsinki Declaration. All patients read and signed an informed consent form 
prior to enrollment. 
Thirty-nine healthy participants were recruited among family members of patients included in the 
database at CCBR (https://dk.ccbr.com/ccbr-aalborg) and the clinical trial unit C4Pain 
(www.C4Pain.com), Aalborg, Denmark. The control subjects had X-ray images taken of their knee 
and KL was evaluated. The exclusion criteria included painful OA, psychiatric conditions 
preventing the subject from participating in the study, pregnancy, previous/current drugs or alcohol 





abuse, previous neurological or musculoskeletal disorders, lack of collaboration ability and subjects 
unable to abstain from analgesic medication for at least 24 h prior to the knee pain assessment 
(Demographic showed in Table 1). 
2.2 Pain assessment 
The peak pain intensities within the last 24 hours were collected (visual analogue scale [VAS]) 
from both patients and healthy participants. The participants were asked to rate their pain intensity 
on a scale from “0 -10” in which “0” represents “no pain” and “10” represents “worst pain 
imaginable”. 
2.3 Outcome measure 
Patients completed the KOOS, a knee-specific questionnaire with five separately reported subscales 
of pain, other symptoms, function in daily living, function in sports/recreation, and knee-related 
quality of life 
21
. The subscale scores represent the average of all items in the subscale standardized 
to a score from 0 to 100 with high scores representing less pain and symptoms and high function 
and quality of life. The KOOS-4 is calculated as the average of each of the four subscales for pain, 




2.4 Blood sampling and serum isolation 
Venous blood was collected following standard venipuncture procedures between 07:30-09:00 in 
the morning. Nine ml of whole blood was withdrawn in an untreated tube. After collection the 
whole blood was left at room temperature for 15 minutes to allow coagulation to occur. The 
coagulated blood was removed centrifuging at 3000 RPM for 15 minutes and the serum obtained 
was transferred into a clean tube and stored at -80˚C. 
2.5 Cytokines array detection 





The relative levels of 92 inflammation-related proteins were analyzed using the inflammation panel 
(Olink Bioscience, Sweden) based on multiplex extension assay (PEA) 
23,24
. Analyses were 
performed at BioXpedia A/S, Aarhus, Denmark. Proteins that have been assessed and their Uniprot 
identities are listed in [38]. The multiplex PEA technology allows assessment of protein using 
paired oligonucleotide-conjugated antibodies as probe for each protein. Each pair of probes 
recognizes a specific protein and only after the binding the oligonucleotides can hybridize allowing 
the amplification of the new DNA double strand. The product of the amplification (amplicon) is 
then detected and quantified using a highly sensitive technology; i.e., the microfluidic real-time 
PCR platform. This PCR platform cannot be used to report absolute quantification but only relative 
protein values, allowing comparison between groups of samples. 
In brief, 1 μl of the serum sample was mixed with a 3 μl incubation mix containing 92 pairs of 
probes, each consisting of an antibody labeled with a unique corresponding DNA oligonucleotide. 
All samples were spiked with two incubation controls (green fluorescent protein and 
phycoerythrin), one extension control and one detection control. The mixture was incubated at 4°C 
overnight. Then, a 96 μL extension mix containing PEA enzymes and PCR reagents was added, and 
the samples incubated for 5 min at room temperature, before the plate was transferred to the thermal 
cycler for an initial DNA extension at 50°C for 20 min followed by 17 cycles of DNA 
amplification. A 96.96 Dynamic Array IFC (Fluidigm, South San Francisco, CA, USA) was 
prepared and primed according to the manufacturer’s instructions. In a new plate, 2.8 μL of sample 
mixture was mixed with 7.2 μL detection mix from which 5 μL was loaded into the right side of the 
primed 96.96 Dynamic Array IFC. The unique primer pairs for each protein were loaded into the 
left side of the 96.96 Dynamic Array IFC, and the protein expression program was run in 
BioMarkTM HD Fluidigm real‐time PCR (Fluidigm, South San Francisco, CA, USA) according to 
the instructions for Proseek. Results were presented in Normalized Protein Expression (NPX) in 





log2. Using NPX Manager, the quantification cycle (Cq) values, generated in the real-time PCR, 
were normalized against extension and interplate controls and a correction factor. Subtracting the 
extension control from the Cq-value of every sample corrects for technical variation and subtracting 
the interplate control compensates for possible variation between runs. Further, the NPX was 
calculated by normalization against the calculation correction factor. The NPX was calculated in 
three steps from the Cq‐values: 
(I) ΔCqsample = Cqsample − Cqextensioncontrol, 
(II) ΔΔCq = ΔCqsample − ΔCqinterplatecontrol, 
(III) NPX = Correction factor − ΔΔCqsample. 
Validation data for all antibodies used in this panel and the performance of each assay are available 
at the manufacturer’s webpage (www.olink.com). With this calculation, NPX values correspond to 
a relative quantification between samples and with a high NPX value corresponding to a high 
protein concentration. Limit of detection (LOD) was determined for each biomarker based on the 
mean value of triplicate negative controls analyzed in each run. Cut-off for LOD was set arbitrarily 
at 30% in order to avoid false positivity and negativity in the expression of the samples that were 
used for further statistical analyses. 
2.6 Statistical analysis 
Distribution of protein values was evaluated using the Shapiro-Wilk normality test. To test for 
differences in biomarker levels between patients with OA and healthy participants, paired 
independent-sample t-tests were performed on normally distributed markers, and the Mann-
Whitney U signed rank tests were used on non-normally distributed markers. The data is shown in a 
volcano plot, combining p-values (y-axis) with the fold changes (x-axis), thus highlighting 
biomarkers with high or low levels of expression. 





Correlations between markers’ NPX and pain intensity were conducted using Pearson’s correlation 
coefficients for the normally distributed data, while Spearman’s correlations were used for the non-
normally distributed data. All significant values were corrected for multiple comparisons by the 
False Discovery Rate (FDR) method with a PFDR-value ≤ 0.008. 
Linear regression models were constructed using two models to identify inflammatory markers 
predicting clinical pain in KOA patients. Model 1 included as predictors all the markers that were 
significant in the t-tests and Mann-Whitney U tests. In model 2, backwards selection was applied to 
model 1 to identify independent predictors for clinical pain. 
The data analysis was performed in SPSS software V.25 (IBM, Armonk, New York, USA). P<0.05 
was considered significant.  All statistical significance was corrected using the Benjamini and 
Hochberg false discovery rate (FDR) 
25
, using GraphPad Prism version 8 for Windows 10 
(GraphPad Software, La Jolla, CA, USA). 
3. Results 
3.1. Differences in serum levels of inflammatory cytokines between healthy participants and 
patients with osteoarthritis 
Seventy-two markers were defined as valuable due to the LOD, representing more than 30% of 
expression in KOA patients and healthy participants (Supplementary figure 1, Supplemental Digital 
Content 1, http://links.lww.com/CJP/A626). Moreover, the brain-derived neutrophic factor (BDNF) 
was not evaluated due to the facility’s internal problem. Levels of fifteen cytokines (Table 2) were 
found to be significantly different in the KOA patients’ samples as compared with the healthy 
participants (Figure. 1). 
3.2. Associations between Inflammatory makers and pain intensity in patients with KOA 
Patient data showed a positive significant Pearson’s correlation between clinical pain and FGF-21 
(R=0.235, P=0.008, adjusted by FDR) and a positive Spearman’s correlation was found between 





pain and 4E-PB1 expression (R=0.233, P=0.008, adjusted by FDR). None of the other cytokines 
evaluated were associated with pain intensity or KOOS-4. Furthermore, linear regression models 
aiming to predict clinical pain were established to investigate the predictive value of inflammatory 
markers. Model 1 consists of all the significant variables in the t-tests and Mann-Whitney U tests, 
with predictive values (R
2
) of 15.0% and identified IL6 (P=0.003; 95% CI: -0.7 to -0.15), DNER 
(P=0.026; 95% CI: 0.02 to 0.42), CSF-1 (P=0.016; 95% CI: 0.06 to 0.56), FGF-21 (P=0.008; 95% 
CI: 0.07 to 0.43), and TWEAK (P=0.033; 95% CI: -0.51 to -0.02) as significant factors (Table 3). 
Model 2 used backwards selection of the significant variables included in model 1 and identified 
IL6 (P<0.001; 95% CI: -0.62 to -0.19), DNER (P=0.05; 95% CI: -0.007 to 0.38), CSF-1(P=0.015; 
95% CI: 0.051 to 0.48), FGF-21 (P=0.002; 95% CI: 0.095 to 0.43), and TWEAK (P=0.001; 95% 
CI: -0.56 – 0.15) as significantly independent parameters for clinical pain with a predictive value 
(R
2
) of 16.0% (Table 3, model 2). 
4. Discussion 
This study is the first to evaluate a large panel of different inflammatory biomarkers in patients with 
KOA compared with healthy participants. When compared to healthy participants, patients with 
KOA were found to have ten cytokines with significantly lowered expression in the serum, and five 
cytokines with higher expression levels. Further, FGF-21 and 4E-PB1 were found to be 
significantly correlated to pain intensity in patients with KOA, whereas no correlations were found 
between marker expression and KOOS-4 in patients. The linear regression model showed IL6, CSF-
1, FGF-21, and TWEAK as significant independent parameters for pain intensity. 
Cytokines in osteoarthritis with low expression levels 
CASP-8 
Caspases are usually proteins related with cellular apoptosis, but studies have shown that protein of 
this family may also be involved in induction of inflammation 
26
. Moreover, previous studies have 





shown that in particular CASP-8 may drive T cell activation, cell motility, and tumor metastasis, 
and it has been demonstrated that the early action of CASP-8 is related to the activation of 
osteoblasts 
27,28
. As found in the present study, the significant reduction of this protein in patients 
with KOA compared with healthy participants could indicate that the possible downregulated 
osteoblast activity may hamper bone formation. 
EN-RAGE and DNER 
Newly identified extracellular receptors for advanced glycation end-products (EN-RAGE or Protein 
S100-A12) and Delta and Notch-like epidermal growth factor related (DNER) are proteins 
abundantly expressed by immune cells including granulocytes, monocytes, macrophages as well as 
fibroblasts and specifically DNER is expressed in dendrites and cell bodies of CNS neurons [4]. 
They generally recruit or stimulate inflammatory mediators, or are part of a cellular network, which 
influences immunological significance. Furthermore, they are known to be expressed locally in 
synovial tissues 
29
. Strong expression of human EN-RAGE in synovial inflammation is found in 
synovial fluid and serum in rheumatoid arthritis (RA) and other inflammatory disease 
30
. This 
protein is expressed and secreted at local sites of inflammation in synovitis expressed by 
granulocytes starting inflammatory processes in the synovium, thus resulting in chronic arthritis 
30
. 
Proteins of the same family have been found in the synovial fluid of OA patients, and the elevated 
levels of this protein may predict joint destruction 
31
. In this study, we showed a significant 
reduction of these proteins in patients with KOA compared with healthy participants,  which may 




Another marker found to be dysregulated is axis inhibition protein (AXIN1). AXIN1 is a 
cytoplasmic protein expressed in the cartilaginous area of the axial and appendicular skeleton 





during embryonic axis development, and is a negative regulator of the Wnt signaling pathway by 
downregulation of β-catenin 
33,34
. A preclinical study has shown that a deletion of this protein in the 
chondrocyte of mice leads to OA-like degeneration 
35
. In this study, a lower level of serum 
expression was found in serum of patients with KOA compared with healthy participants 
confirming that reduction of this marker can be related with OA’s pathogenesis. 
STAMPB 
STAMBP is a deubiquitinase enzyme and a member of the Jab1/MPN metalloenzyme (JAMM) 
family of deubiquitinating enzymes (DUBs) 
36
. STAMBP is involved in the signal transduction of 
JAK-STAT cascade binding to the SRC Homology 3 domain of the signal-transducing adaptor 
molecule STAM 
37
. STAMBP plays a critical role in cytokine-mediated response and induces the 
signaling that can de-ubiquitinate early and late endosome cargo proteins from progressing to 
lysosome compartmentalization 
38
. An in vitro study shows that the involvement of STAMBP in the 
regulation of inflammasomes which regulate innate immune responses by facilitating maturation of 
inflammatory cytokines 
37,39
. In the cited study, the authors show how blocking STAMBP 
deubiquitinase activity decreases levels of specific inflammation cytokines like IL-1b 
37
. In this 
study, the systemic levels of STAMBP were found to be decreased in patients with KOA compared 
with healthy participants. 
SIRT2 
Srtuin2 (SIRT2) is a member of the sirtuin family, which is a group of nicotinamide adenine 
dinucleotide-dependent deacetylases 
40
, mostly involved in the regulation of different processes like 
proliferation, metabolism, apoptosis, and inflammatory responses 
41,42
. Studies have reported that 
SIRT2 is involved in the regulation of neurological diseases and neuroinflammation 
43,44
. Moreover, 
SIRT2 inhibits inflammation through de-acetylation of the NF-κBp65 protein and inhibits NF-κB-
dependent pro-inflammatory cytokine expression 
45,46
. 





A preclinical study in an animal model of arthritis has confirmed SIRT2 action as an arthritis 
suppressor, showing that a deficiency of SIRT2 led to a severe arthritic phenotype 
47
. A recent 
preclinical study revealed the important role of SIRT2 in regulating neuroinflammation and 
neuropathic pain development, highlighting that a high expression of SIRT2 alleviated neuropathic 




In this study, lower expression levels of SIRT2 were found in serum from patients compared with 
controls confirming that the inhibition of this marker is not only related to the pro-inflammatory 
response in these patients but also to their painful condition. 
SCF 
The stem cell factor (SCF) is produced by cells such as fibroblasts and it plays an important role in 
the differentiation and proliferation of cells by acting in a paracrine manner 
49
. Preclinical studies 
show SCF as a ligand for c-Kit which is a receptor tyrosine kinases expressed on a specific 
subpopulation of sensory neurons, and may relate to the action of SCF with pain regulation both 
peripherally and centrally 
50,51
. SCF has been found to be downregulated in patients with KOA 
compared with healthy participants, which could confirm the involvement of this factor in the 
activation of the pathways involved in the regulation of pain present in these patients. 
4E-BP1 
The eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) inhibits the cap-binding 
translation initiation factor eIF4E from interacting with other elongation factors 
52
. This is a key 
regulatory process in translation involved in the regulation of cell physiology through the 
modulation of protein synthesis 
52
. 4E-BP1 is the target of action of intracellular signaling, the 
serine–threonine kinase mammalian target of rapamycin (mTOR), which regulates cell 
proliferation, cell growth, and synaptic plasticity downstream of multiple stimuli such as glutamate, 





growth factors, and cytokines 
53,54
. 4E-BP1 is also expressed in neurons in the dorsal horn of the 
spinal cord, and in peripheral nerves 
55,56
. Preclinical evidence shows that removal of 4E-BP1 leads 
to enhanced eIF4F complex formation in the spinal cord and to mechanical hypersensitivity and 
increased response to noxious chemical and inflammatory stimuli 
57
. The present study shows that 
patients with KOA present significantly lower serum expressions of this protein, and found it 
positively correlated with pain intensity. This may confirm the connection between pain, 
inflammation process, and the reduction of this protein showed in the literature. 
TWEAK 
Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) is a member of the TNF 
superfamily, which has effects including pro-inflammatory activities on epithelial and endothelial 
cells 
58
 as well as proliferation enhancing effects on endothelial cells and astrocytes 
59,60
. A previous 
study demonstrated that TWEAK can induce the production of pro-inflammatory cytokines and 
chemokines by normal human dermal fibroblasts and synoviocytes obtained from RA and advanced 
osteoarthritis patient tissues 
61
. In contrast to the pro-inflammatory functions of this protein, our 
results highlight a significant reduction in the sera expression in patients with KOA. Moreover, 
linear regression showed that TWEAK is an independent factor for pain intensity in KOA patients. 
uPA 
The urokinase plasminogen activator (uPA) is one of the two types of plasminogen activators (PAs) 
identified in mammals, which catalyze the conversion of the zymogen plasminogen into plasmin 
62
. 
Plasmin is a protease with the capacity of degrading most of the extracellular proteins, including 
proteoglycans, directly or indirectly through the activation of pro-collagenase into collagenase 
63
. 
Clinical evidence suggests a contribution of the PA system to joint pathogenesis in osteoarthritis 
(OA) and RA showing that expression levels of active uPA protein in OA synovium are not 
detectable in patients with OA 
64
. In this study, significantly lower levels of uPA were found in the 





serum of patients with KOA compared with healthy participants, which could confirm previous 
findings in which lower levels of this marker were associated with the OA state. 
Cytokines in osteoarthritis with high expression levels 
IL-6 
Interleukin-6 (IL-6) is a pro-inflammatory cytokine that plays a role in innate immunity and joint 
inflammation in arthritic diseases 
65
. IL-6 is a ligand for IL-6 receptor (IL-6R), which is expressed 
on the cell surface or can be found in the circulation in its soluble form, IL-6 receptor (sIL-6R); the 
bind of IL-6 to its receptors can activate different pathways on several different cell types which 
includes immune cells and osteoclasts 
65,66
. Studies in animal models show that IL-6 also acts on 
nociceptive neurons, highlighting it as a potential pain modulator 
67,68
. Further, IL-6 has been found 
to be highly expressed in animal models and in patients with painful KOA 
18,19,69
. This study 
confirmed the augmented expression of serum levels of IL-6 in patients with KOA compared with 
controls adding evidence to the inflammation present in this pathology. Moreover, the linear 
regression highlighted its negative association with the pain intensity, suggesting that higher serum 
levels of this cytokine can have a different mode-of-action in the joint and in the circulation in 
relation to pain in the KOA cohort. 
CSF-1 
CSF-1, a member of the hematopoietic CSF family, is a key regulator for the survival, proliferation, 
and differentiation of macrophage populations, including osteoclasts 
70,71
. CSF-1 acts on its 
receptor, CSF-1R, and this signaling is evaluable also at central nervous system level because of the 
expression on microglia and possibly neurons 
72–74
. Signaling of CSF-1/CSF-1R has been found to 
be involved in several pathological conditions 
72,75
 and in a model of arthritis 
76
. CSF-1 may play a 
critical role in pain and arthritic diseases 
72,77
, and previous studies proposed its action on microglia 
to control nerve injury–induced neuropathic pain 
78,79
. Moreover CSF-1 can also act peripherally to 





regulate pain, probably by its action on macrophages in tissues and possibly in nerves 
80
. In this 
study, highly significant levels of CSF-1 were found in serum of patients with KOA, and the linear 
regression model explained its independent positive correlation with the pain intensity in these 




Fibroblast growth factor-21 (FGF-21) is a member of the FGF superfamily that acts as an endocrine 
hormone with the function of a metabolic regulator 
82
. FGF-21 can be released into the circulation 
and it has been reported that FGF-21 can be detected in serum and synovial fluid (SF) samples of 
patients with RA and OA, rather than at the site of local joint tissue in OA patients 
83
.  A recent 
study showed how the FGF-21 concentration in serum from patients with OA was independently 
correlated with the severity of knee OA 
84
. Our results confirm that high expression levels of this 
hormone circulate in the serum of patients with KOA, thus indicating that it is a significantly 
correlated and independent factor for pain intensity in evaluated patients. 
MCP-3 
Monocyte chemotactic protein 3 (MCP-3, known as CCL7) is one of 28 members of the CC 
subfamily of chemokines. A previous animal study showed its involvement in neuropathic pain and 
pain plasticity in the spinal cord of the rat after nerve ligation 
85
. After dorsal root ganglia 
activation, IL-6 signaling causes a high upregulation of the MCP-3 gene which activates spinal 
microglia and which may promote the spinal sensitization and facilitation of ascending pain 
transmission 
86
. In this study, high levels of MPC-3 were found in serum of patients with KOA in 
accordance with previous literature pointing towards the cooperative action of IL-6 and MPC-3 in 
pain sensation. 
LAP TGF-beta-1 





TGF-β1 is secreted as a homodimer together with its latency-associated pro-peptide LAP. Its 
association with LAP prevents binding of the TGF-β1 to cell receptors which uncouples the time of 
growth factor secretion from the time of growth factor action 
87
. In this study, the level of the latent 
form of TGF-β1 was found significantly increased in serum from patients with KOA compared with 
healthy participants. This may indicate that the active polypeptide could be released and act in the 
area of the pathology. 
Inflammatory markers and pain in knee osteoarthritic patients 
Several previous clinical and preclinical studies have shown pro-inflammatory cytokines IL-1b, IL-6, IL-8, and TNFα 
and anti-inflammatory cytokines such as IL-10 in synovial fluid (SF), serum, and at different cellular levels (e.g., 
sensory neurons and chondrocyte) associated to the degree of osteoarthritic and OA pain 
18,88–90
. The current study 
found that FGF-21 and 4E-BP1 were positively associated with pain intensity and highlighted TWEAK, FGF-21, CSF-
1, and IL6 as independent factors predicting pain intensity in KOA patients. High levels of IL-6, in synovial fluid and 
serum were previously found to be positively associated with pain outcomes 
16,90
. On the contrary, the present work 
highlighted a negative association of IL-6 serum levels with clinical pain, indicating that IL-6 might have different 
mode-of-action locally (the synovial fluid) and systemically (e.g. in serum). Moreover, growth factor FGF-21 has been 
shown to be highly expressed in serum and SF in patients with RA and also with detectable levels in patients with OA 
83
. This study confirms the high serum levels of FGF-21 in patients with OA, the positive correlation and its significant 
value as an independent factor for the pain intensity, thereby giving the first indication of a potential involvement of this 
growth factor in the pain status of OA patients. Moreover, this study showed low expression levels of 4E-BP1, a factor 
involved in the mTOR pathways, which in a preclinical study has been shown to be expressed in neurons in the dorsal 
horn and in peripheral nerves, and the depletion of which can lead to mechanical hypersensitivity and increased 
response to noxious stimuli 
55,56
. Future studies are encouraged to assess the associations between inflammatory profiles 
and pain hypersensitivity in patients with OA. 
Limitation in this study can be represented by levels of tumor necrosis factor alpha (TNFα), a marker involved in the 
inflammation and pain process although previously described as a detectable marker in OA 
14
, that were not higher than 
the minimum level of detection (LOD). To avoid false positive or negative results during the statistical data 
processing, this specific marker was excluded from the analysis. 
In conclusion, the present study found patients with KOA to have ten cytokines with significantly lowered expression in 
the serum and five cytokines with higher expression levels, when compared to healthy participants. Specifically, FGF-
21 and 4E-BP1 were associated with pain in KOA, and TWEAK, FGF-21, CSF-1, IL6 were identified as independent 
predictors for pain intensity. Further studies are needed in order to validate the specific systemic involvement of these 
inflammatory markers with the pain in KOA patients. 
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Figure 1. Volcano plot of differential serum inflammatory marker expressions. Statistical 
significance versus fold change is shown on the y and x axes, respectively. The volcano plot of data 
shows the Normalized Protein eXpression (NPX) for the 72 markers in KOA patients compared 
with healthy controls. a) Black full dots shows significant markers with PFDR-value <0.01 (circles 
represent results obtained with Mann-Whitney U; triangles represent results obtained with t-test). b) 
Empty circles represent significant markers with PFDR-value >0.01 and non-significant markers with 
P-value >0.05. Normalized Protein eXpression (NPX) is an Olink’s arbitrary unit expressed in Log2 
scale for markers expression levels. 
  





Table 1. Demographics 
 Controls (n = 40) KOA patients (n = 127) 
 





   
Age (years) 68.46 ± 3.13 68.82 ± 9.15 
   
Kellgren Lawrence (1-4) 1.43 ± 0.59 3.74 ± 0.49 
   
BMI (kg/m2) 26.71 ± 4.21 29.37 ± 4.79 
   
Table 1. Demographics of patients and controls enrolled in the study. Data for age, Kellgren 
Lawrence scale, and BMI are presented as mean ± standard deviation (SD). 
  





Table 2. Expression markers profile 





Extracellular newly identified receptor for advanced glycation end-products (EN-
RAGE) 
9.29e-008 
Delta and Notch-like epidermal growth factor-related receptor (DNER) 0.00006 
Axin-1 (AXIN1) 7.4e-007 
STAM-binding protein (STAMBP) 0.00001 
SIR2-like protein 2 (SIRT2) 0.00005 
Stem cell factor (SCF) 0.0002 
Eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) 0.0003 
Tumor necrosis factor (Ligand) superfamily, member 12 (TWEAK) 0.002 
Urokinase-type plasminogen activator (uPA) 0.004 
Highly expressed markers  
Interleukin-6 (IL-6) 0.00002 
Macrophage colony-stimulating factor 1 (CSF-1) 0.001 
Fibroblast growth factor 21 (FGF21) 0.001 
Monocyte chemotactic protein 3 (MCP-3) 0.006 
Latency-associated peptide transforming growth factor beta-1 (LAP TGF-beta-1) 0.009 
 
Table 2. Markers significantly dysregulated between KOA patients and healthy controls. The P-









Table 3. Linea regression models 
 
Table 3. Linear regression models of the inflammatory markers showing association between marker serum levels and 
pain intensity. Model 1 consists of all the parameters and model 2 has been designed using backwards selection. R2 
indicates variance of pain intensity.  Standardized coefficients refer to how many standard deviations a dependent 
variable will change per standard deviation increase in the predictor variable. 95% confidence intervals of standardized 
coefficient. 









   0.154 
 CASP-8 
 
-0.123 [95% CI: -0.40 to 0.15] 0.385  
 EN-RAGE 
 
0.187 [95% CI: -0.07 to 0.44] 0.163  
 AXIN1 
 
-0.092 [95% CI: -0.33 to 0.14] 0.448  
 STAMPB 
 
0.176 [95% CI: -0.19 to 0.55] 0.354  
 IL6 
 
-0.427 [95% CI: -0.7 to -0.15] 0.003  
 SIRT2 
 
-0.009 [95% CI: 0.38 to -0.36] 0.963  
 DNER 
 
0.227 [95% CI: 0.02 to 0.42] 0.026  
 SCF 
 
-0.142 [95% CI: -0.35 to 0.07] 0.197  
 4E-BP1 
 
0.093 [95% CI: -0.19 to 0.37] 0.509  
 CSF-1 
 
0.306 [95% CI: 0.06 to 0.56] 0.016  
 FGF-21 
 
0.246 [95% CI: 0.07 to 0.43] 0.008  
 TWEAK 
 
-0.265 [95% CI: -0.51 to -0.02] 0.033  
 uPA 
 
-0.127 [95% CI: -0.34 to 0.09] 0.247  
 MCP-3 
 
-0.120 [95% CI: -0.34 to 0.10] 0.275  
 LAP TGF-beta-1 
 
-0.034 [95% CI: -0.23 to 0.16] 0.732  
2 
 
   0.163 
 IL6 
 
-0.406 [95% CI: -0.62 to -0.19] <0.001  
 DNER 
 
0.185 [95% CI: -0.007 to 0.38] 0.058  
 CSF-1 
 
0.264 [95% CI: 0.051 to 0.48] 0.015  
 FGF-21 
 
0.264 [95% CI: 0.095 to 0.43] 0.002  
 TWEAK 
 
-0.355 [95% CI: -0.56 – 0.15] 0.001  








Sup.Figure.1 Limit of detection determined for each marker based on the mean value of triplicate 
negative controls analyzed in each run. Only 72 markers with values above LOD of more 
than 30% were analyzed.  
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